0001104659-21-150679.txt : 20211216 0001104659-21-150679.hdr.sgml : 20211216 20211216194737 ACCESSION NUMBER: 0001104659-21-150679 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211214 FILED AS OF DATE: 20211216 DATE AS OF CHANGE: 20211216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dougan Brady W CENTRAL INDEX KEY: 0001878020 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39532 FILM NUMBER: 211499208 MAIL ADDRESS: STREET 1: 35 WILSHIRE ROAD CITY: GREENWICH STATE: CT ZIP: 06831 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Humacyte, Inc. CENTRAL INDEX KEY: 0001818382 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 851763759 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2525 EAST NORTH CAROLINA HIGHWAY 54 CITY: DURHAM STATE: NC ZIP: 27713 BUSINESS PHONE: 919-313-9633 MAIL ADDRESS: STREET 1: 2525 EAST NORTH CAROLINA HIGHWAY 54 CITY: DURHAM STATE: NC ZIP: 27713 FORMER COMPANY: FORMER CONFORMED NAME: Alpha Healthcare Acquisition Corp. DATE OF NAME CHANGE: 20200716 4 1 tm2135715-2_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-12-14 0 0001818382 Humacyte, Inc. HUMA 0001878020 Dougan Brady W 2525 EAST NORTH CAROLINA HIGHWAY 54 DURHAM NC 27713 1 0 1 0 Common Stock 2021-12-14 4 S 0 23694 9.798 D 786467 D Common Stock 2021-12-14 4 S 0 76306 9.325 D 710161 D Common Stock 2021-12-15 4 S 0 125000 8.885 D 585161 D Common Stock 2021-12-16 4 S 0 75000 9.000 D 510161 D Common Stock 20452504 I By Ayabudge LLC Common Stock 1148240 I By spouse A portion of this sale is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the purchase by Ayabudge LLC of 1,522,500 shares of the Issuer's common stock on August 26, 2021, at a price per share of $10.00. The Reporting Person has paid the Issuer $71.21, representing the full amount of profit realized in connection with this sale. The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.50 to $10.06. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.825 to $9.49. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.68 to $9.43. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.79 to $9.33. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. /s/ Brady W. Dougan by Dale A. Sander as Attorney-in-Fact 2021-12-16